Clinical trial costs have steadily increased over the past decade, driven by rising staffing and material expenses, complex trial designs, and looming global tariffs. In a recent article by Clinical Trials Arena, industry experts—including Heather Purvis, Director of Operations at Title21 Health Solutions—weigh in on the challenges and potential solutions for managing these growing costs.
Heather highlights the critical role that highly trained personnel play in trial operations and how shrinking federal funding is intensifying the cost burden:
“You need highly skilled individuals who can pivot and be critical thinkers. That takes a lot of experience and training, so these staff members are highly sought after. Not only this but now, staff are being asked to do more with less because of the cuts in the funding. With the funding removal, the cost of staff is going to increase even further.”
As clinical research evolves, strategies like streamlining trial designs, leveraging biomarkers, and automating manufacturing are being explored to improve efficiency without compromising safety or outcomes.
Read the full article on Clinical Trials Arena to explore more expert perspectives on how the industry is adapting: www.clinicaltrialsarena.com/features/how-pharma-managing-rising-trial-costs/
